People paying privately for weight-loss drug Mounjaro in the UK face a rise in the cost of the treatment after manufacturer ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

As the Dec. 31 end to federal subsidies for federal health care nears, pressure is mounting on insurers, providers, and the ...

Drivers of revenue growth included more customers using multiple chronic condition programs as well as strong adoption of GLP ...

Danone is introducing an Oikos brand drink targeting U.S. consumers using weight loss medications such as Wegovy, pledging ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Medicare covers weight loss drugs including Ozempic under specific conditions when the drug also has potential use cases beyond weight loss.

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Healthcare, IT services, and communications stocks are pressured by competition, slowing growth, and sector-wide bearish ...